Clinical Trial to Evaluate the PK Interactions of YHR2402 Monotherapy and YHR2402 and YHR2403 Co-Administration in Healthy Volunteers

Phase 1 Completed 26 enrolled Yuhan Corporation

RandomizedCrossoverOpen-labelTreatment

Summary

An open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetic interactions and safety after co-administration of YHR2402 and YHR2403 compared to the administration of YHR2402 independently in healthy subjects

Timeline

Start: 2024-10-04
Primary completion: 2024-11-06
Completion: 2024-11-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	YHR2402	Unknown	—	—
Subject	YHR2403	Unknown	—	—

Indications

No indication recorded.